Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 (COVID-PREVENT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04416048|
Recruitment Status : Terminated (Due to lower COVID-19 cases and therefore difficulties with the recruitment.)
First Posted : June 4, 2020
Last Update Posted : January 12, 2022
Patients with moderate to severe COVID-19 present a very high risk of thromboembolic disease.This multicenter, prospective, randomized, event-driven study evaluates rivaroxaban compared with standard of care with low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) at prophylactic doses comparing D-dimer levels and the seven-category ordinal scale recommended by the WHO 7 days post randomization in patients with moderate to severe COVID-19.
Experimental intervention/Index test:
Patients randomized into the rivaroxaban arm will receive rivaroxaban 20 mg once daily (OD) until day 7 post randomization or hospital discharge, whichever occurs later, followed by a 28-day-phase of prophylactic anticoagulation with rivaroxaban 10mg OD. Subjects with an eGFR between 30 and 50ml/min/1,73m2, will receive 15mg instead of 20mg OD.
Control intervention/Reference test:
The control group will receive standard of care including LMWH or UFH as thromboprophylaxis.
Duration of intervention per patient:
The total duration of the study treatment is flexible. For out-patients 7 days of therapeutic anticoagulation will be accompanied by 28 days-phase of prophylactic anticoagulation, summing up to 35 days. For subjects that require hospitalization, the duration of therapeutic anticoagulation will be at least 7 days or prolonged until discharge if hospitalized for more than 7 days post randomization.
After discharge from the hospital the subject receives 28 days of thromboprophylaxis with rivaroxaban. No study medication will be given past day 60 post randomization. This adds up to a study duration between 35 and 60 days depending on the duration of the hospital stay.
Follow-up per patient:
The study has a follow-up of 60 days.
Experimental and/or control off label or on label in Germany:
Rivaroxaban has been approved for multiple indications worldwide. Over 100,000 subjects have been studied from Phase 1 through multiple large Phase 4 studies in multiple settings, e.g. for the reduction in the risk of stroke and systemic embolism in arterial fibrillation, deep vein thrombosis and pulmonary embolism, major cardiovascular events. The drug had not been studied in patients with COVID-19 as an anticoagulant agent, yet.
|Condition or disease||Intervention/treatment||Phase|
|COVID-19||Drug: Rivaroxaban Other: Standard Of Care (SOC)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||111 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||A multicenter, prospective, randomized, event-driven study.|
|Masking:||None (Open Label)|
|Masking Description:||Central randomization will be implemented in this study. Subjects will be randomly assigned to 1 of 2 treatment groups based on a computer-generated randomization schedule prepared before the study under the supervision of the sponsor. The randomization will be stratified by site, gender, age, kidney function (subjects with eGFR ≥30 mL/min/1.73m2 and <50 mL/min/1.73m2 versus subjects with eGFR ≥50 mL/min/1.73m2), history of CAD or heart failure and oxygen demand on admission to the hospital. The computer system will assign a unique treatment code, which will dictate the treatment assignment and study drug kits for the subject. The requestor must use his or her own user identification and personal identification number when contacting the system and will then give the relevant subject details to uniquely identify the subject.|
|Official Title:||Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19)|
|Actual Study Start Date :||November 30, 2020|
|Actual Primary Completion Date :||July 20, 2021|
|Actual Study Completion Date :||July 20, 2021|
Subjects will receive treatment with rivaroxaban. (for more information see intervention description)
Treatment with Rivaroxaban 20 mg (15 mg for subjects with an eGFR ≥30 mL/min/1.73m2 and <50 mL/min/1.73m2) once daily (OD) for at least 7 days. In case of hospitalization for more than 7 days, the therapeutic treatment with rivaroxaban will be continued for the duration of the hospital stay until discharge. After at least 7 days of therapeutic treatment with rivaroxaban or after hospital discharge, the study dose of rivaroxaban will be adjusted as follows. Patients randomized to the rivaroxaban study arm will reduce daily dosage to 10 mg OD, provided that they were not diagnosed with a condition requiring continued therapeutic anticoagulation. Thromboprophylaxis therapy will be given for 28 days up to day 35 post randomization or even longer. If the patient cannot be discharged from the hospital prior to day 35 post randomization, the thromboprophylaxis phase will also start upon hospital discharge, but is then shorter than 28 days, because the study ends at day 60 post randomization.
Other Name: XARELTO®
Standard of Care
Subjects will receive standard of care (SOC) treatment SOC with prophylactic LMWH or UFH
Other: Standard Of Care (SOC)
Standard of care treatment
- D-dimer level [ Time Frame: 7 days post randomization ]
- Seven-category ordinal scale recommended by the WHO [ Time Frame: 7 days post randomization ]
- Composite endpoint of venous thromboembolism (DVT and/or fatal or non-fatal PE), arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause death or progression to intubation and invasive ventilation [ Time Frame: 35 days post randomization ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04416048
|Principal Investigator:||Ulf Landmesser, Prof. Dr.||Charite University, Berlin, Germany|
|Principal Investigator:||Co-PI: Andreas M. Zeiher, Prof. Dr.||Johann Wolfgang Goethe-University, Frankfurt am Main, Germany|
|Principal Investigator:||Co-PI: Steffen Massberg, Prof. Dr.||Ludwig-Maximilians - University of Munich|
|Principal Investigator:||Co-PI: Ursula Rauch-Kröhnert, Prof. Dr.||Charité University, Berlin, Germany|
|Principal Investigator:||Co-PI: Jan Beyer-Westendorf, Prof. Dr.||University Hospital Carl Gustav Carus at the Technical University of Dresden|